Clarus' Jatenzo Suffers From Off-Label Concerns At US Advisory Committee

 
• By Derrick Gingery

Oral testosterone candidate loses close vote as many panelists worry that convenience could spur misuse; REMS could offer reassurance.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers